<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="367599">
  <stage>Registered</stage>
  <submitdate>11/12/2014</submitdate>
  <approvaldate>5/02/2015</approvaldate>
  <actrnumber>ACTRN12615000106538</actrnumber>
  <trial_identification>
    <studytitle>Efficacy and safety of artemisinin-based combination therapy: artesunate-amodiaquine (ASAQ) and artemether-lumefantrine (AL) in the treatment of uncomplicated falciparum malaria in 4 provinces of Burundi</studytitle>
    <scientifictitle>Efficacy and safety of artemisinin-based combination therapy: artesunate-amodiaquine (ASAQ) and artemether-lumefantrine (AL) in the treatment of uncomplicated falciparum malaria in 4 provinces of Burundi</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>NIL</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Uncomplicated falciparum malaria</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Patients with confirmed falciparum malaria from 4 provinces of Burundi (Bujumbura, Makamba, Karuzi and Gitega) will be treated  with artesunate (4mg/kg)-amodiaquine (10 mg/kg) once daily for three days and will be followed for up to 28 days with fixed scheduled clinical and parasitological assessements.  Three formulations of fixed combination tablets of artesunate-amodiaquine will be used: 25/67.5 mg; 50/135mg and 100/270 mg). Number of tablet(s) to be adminsitered is based on body weight according to the national policy.  Once the target number of patients have been enrolled, a second cohort will be treated with artemether (4 mg/kg)-lumefantrine 25 mg/kg) given in two daily doses for three days and will be followed for up to 28 days with fixed scheduled clinical and parasitological assessements.  Fixed combination tablet containing 20 mg artemether and 120 mg lumefantrine will be used: the number of tablets to be administered for the morning and evening dose is based on body weight according to the national policy.  All doses for both treatments will be administered under supervsion of medical staff.</interventions>
    <comparator>None</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>proportion of patients with PCR-corrected adequate clinical and parasitological response according to WHO criteria </outcome>
      <timepoint>Day 28</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of adverse events. Known or possible adverse events associated with ASAQ include anorexia, abdominal pain, nausea, fatique, drowziness, dizziness, insomnia and cough.  Known or possible adverse events associated to AL include fever, cough, vomiting, anorexia and headache</outcome>
      <timepoint>Day 28</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>children aged 6 months to 10 years
monoinfection with P falciparum confirmed by microscopy
parasitemia between 1000-200000 parasites (asexual) per microliter
fever (equal or greater than 37.5 celsius) or history of fever within past 24 hours
able to swallow oral medication 
ability and willingness to follow protocol procedures and schedule of assessments
written informed consent from parent or guardian</inclusivecriteria>
    <inclusiveminage>6</inclusiveminage>
    <inclusiveminagetype>Months</inclusiveminagetype>
    <inclusivemaxage>10</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>presence of danger and signs of severe malaria
mixed infection or infection of than P. falciparum detected by microscopy
severely malnourished
fever due to other diseases (measles, acute lower respiratory tract infection, severa diarrhea); chronic or severe hepatic, renal or cardiac diseases; HIV/AIDS
clinical signs of acute jaundice
abnormal level of granulocytes or liver transaminases
regular medication that could interfere with antimalarial pharmacokinetics;
history of hypersensitivity reactions or contraindications to any medicines being used
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>15/02/2015</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>528</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Burundi</country>
      <state>Karuzi, Makamba, Bujumbura Mairie and Gitega</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>Ministry of Public Health </primarysponsorname>
    <primarysponsoraddress>Avenue de l'Hopital No 5
Bujumbura</primarysponsoraddress>
    <primarysponsorcountry>Burundi</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Ministry of Health</fundingname>
      <fundingaddress>Avenue de l'Hopital No 5
Bujumbura</fundingaddress>
      <fundingcountry>Burundi</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Other Collaborative groups</sponsortype>
      <sponsorname>World Health Organisation</sponsorname>
      <sponsoraddress>20 avenue Appia
1211 Geneva 11</sponsoraddress>
      <sponsorcountry>Switzerland</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Charities/Societies/Foundations</sponsortype>
      <sponsorname>The Global Funds to Fight AIDS,TB  and MALARIA</sponsorname>
      <sponsoraddress>Chemin de Blandonnet 8
1214 Vernier
</sponsoraddress>
      <sponsorcountry>Switzerland</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is an observational study to monitor the efficacy and safety of artesunate-amodiaquine and artemether-lumefantrine in the treatment of uncomplicated falciparum malaria in children recruited from 4 provinces of Burundi. The protocol follows the standard WHO methods for surveillance of antimalrial drug efficacy. </summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Ethics Research Committee, World Health Organisation</ethicname>
      <ethicaddress>20 avenue Appia
1211 Geneva 11</ethicaddress>
      <ethicapprovaldate>17/11/2014</ethicapprovaldate>
      <hrec>RPC623</hrec>
      <ethicsubmitdate />
      <ethiccountry>Switzerland</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Dr NDAYIKUNDA Claudette</name>
      <address>Centre Hospitalier Universitaire de Kamenge
Boulevard du 28 novembre
Bujumbura</address>
      <phone>+257 77721631</phone>
      <fax />
      <email>ndaclau@yahoo.fr</email>
      <country>Burundi</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Dr NDAYIKUNDA Claudette</name>
      <address>Centre Hospitalier Universitaire de Kamenge
Boulevard du 28 novembre
Bujumbura</address>
      <phone>+257 77721631</phone>
      <fax />
      <email>ndaclau@yahoo.fr</email>
      <country>Burundi</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Dr NDAYIKUNDA Claudette</name>
      <address>Centre Hospitalier Universitaire de Kamenge
Boulevard du 28 novembre
Bujumbura</address>
      <phone>+257 77721631</phone>
      <fax />
      <email>ndaclau@yahoo.fr</email>
      <country>Burundi</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>RINGWALD Pascal</name>
      <address>Dr Pascal Ringwald
World Health Organisation 
20 avenue Appia 
1211 Geneva 11</address>
      <phone>+41 22 791 3469</phone>
      <fax />
      <email>ringwaldp@who.int</email>
      <country>Switzerland</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>